Výsledky vyhledávání - Ignacio Garrido‐Laguna

Upřesnit hledání
  1. 1
    TIGIT: a novel immunotherapy target moving from bench to bedside

    TIGIT: a novel immunotherapy target moving from bench to bedside Autor Benjamin L. Solomon, Ignacio Garrido‐Laguna

    Vydáno 2018
    Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Novel Therapeutic Targets in Non-small Cell Lung Cancer

    Novel Therapeutic Targets in Non-small Cell Lung Cancer Autor Filip Janků, Ignacio Garrido‐Laguna, Luboš Petruželka, David J. Stewart, Razelle Kurzrock

    Vydáno 2011
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Combination immunotherapy and radiation therapy strategies for pancreatic cancer—targeting multiple steps in the cancer immunity cycle

    Combination immunotherapy and radiation therapy strategies for pancreatic cancer—targeting multiple steps in the cancer immunity cycle Autor Snehal Gajiwala, Anna Torgeson, Ignacio Garrido‐Laguna, Conan G. Kinsey, Shane Lloyd

    Vydáno 2018
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Response of Histiocytoses to Imatinib Mesylate: Fire to Ashes

    Response of Histiocytoses to Imatinib Mesylate: Fire to Ashes Autor Filip Janků, Hesham M. Amin, Dan Yang, Ignacio Garrido‐Laguna, Jonathan C. Trent, Razelle Kurzrock

    Vydáno 2010
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer

    Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer Autor Anna Torgeson, Shane Lloyd, Dustin Boothe, Randa Tao, Jonathan Whisenant, Ignacio Garrido‐Laguna, George M. Cannon

    Vydáno 2017
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Entrectinib in <i>TRK</i> and <i>ROS1</i> Fusion-Positive Metastatic Pancreatic Cancer

    Entrectinib in <i>TRK</i> and <i>ROS1</i> Fusion-Positive Metastatic Pancreatic Cancer Autor Michael J. Pishvaian, Ignacio Garrido‐Laguna, Stephen V. Liu, Pratik S. Multani, Edna Chow‐Maneval, Christian Rolfo

    Vydáno 2018
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    <i>KRAS</i> Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma

    <i>KRAS</i> Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma Autor Carter Norton, Matthew Shaw, Zachary Rubnitz, Jarrod Smith, Heloisa P. Soares, Christopher Nevala-Plagemann, Ignacio Garrido‐Laguna, Vaia Florou

    Vydáno 2025
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center

    Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center Autor Ignacio Garrido‐Laguna, Filip Janků, Christos Vaklavas, Gerald S. Falchook, Siqing Fu, David S. Hong, Aung Naing, Apostolia M. Tsimberidou, Sijin Wen, Razelle Kurzrock

    Vydáno 2011
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers

    PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers Autor Filip Janků, J. Jack Lee, Apostolia M. Tsimberidou, David S. Hong, Aung Naing, Gerald S. Falchook, Siqing Fu, Rajyalakshmi Luthra, Ignacio Garrido‐Laguna, Razelle Kurzrock

    Vydáno 2011
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors

    KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors Autor Ignacio Garrido‐Laguna, David S. Hong, Filip Janků, Ly M. Nguyen, Gerald S. Falchook, Siqing Fu, J. J. Wheler, Rajyalakshmi Luthra, Aung Naing, Xuemei Wang, Razelle Kurzrock

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer

    A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer Autor Manuel Hidalgo, Elizabeth Bruckheimer, N.V. Rajeshkumar, Ignacio Garrido‐Laguna, Elizabeth De Oliveira, Belén Rubio‐Viqueira, Steven J. Strawn, Michael J. Wick, James Martell, David Sidransky

    Vydáno 2011
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors

    A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors Autor Niharika B. Mettu, Susanna V. Ulahannan, Johanna C. Bendell, Ignacio Garrido‐Laguna, John H. Strickler, Kathleen N. Moore, Robert Stagg, Ann M. Kapoun, Leonardo Faoro, Sunil Sharma

    Vydáno 2021
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    <i>PIK3CA</i> Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

    <i>PIK3CA</i> Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors Autor Filip Janků, Apostolia M. Tsimberidou, Ignacio Garrido‐Laguna, Xuemei Wang, Rajyalakshmi Luthra, David S. Hong, Aung Naing, Gerald S. Falchook, John W. Moroney, Sarina A. Piha‐Paul, Jennifer J. Wheler, Stacy Moulder, Siqing Fu, Razelle Kurzrock

    Vydáno 2011
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring <i>PIK3CA</i> Mutations

    PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring <i>PIK3CA</i> Mutations Autor Filip Janků, Jennifer J. Wheler, Shannon N. Westin, Stacy Moulder, Aung Naing, Apostolia M. Tsimberidou, Siqing Fu, Gerald S. Falchook, David S. Hong, Ignacio Garrido‐Laguna, Rajyalakshmi Luthra, J. Jack Lee, Karen H. Lu, Razelle Kurzrock

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    Personalizing Cancer Treatment in the Age of Global Genomic Analyses: <i>PALB2</i> Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer

    Personalizing Cancer Treatment in the Age of Global Genomic Analyses: <i>PALB2</i> Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer Autor Maria Cristina Villarroel, N.V. Rajeshkumar, Ignacio Garrido‐Laguna, Ana De Jesus‐Acosta, Siân Jones, Anirban Maitra, Ralph H. Hruban, James R. Eshleman, Alison P. Klein, Daniel A. Laheru, Ross C. Donehower, Manuel Hidalgo

    Vydáno 2010
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  16. 16
    PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes

    PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes Autor Filip Janků, Jennifer J. Wheler, Aung Naing, Vanda M. Stepanek, Gerald S. Falchook, Siqing Fu, Ignacio Garrido‐Laguna, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Stacy Moulder, J. Jack Lee, Rajyalakshmi Luthra, David S. Hong, Razelle Kurzrock

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  17. 17
    First‐in‐human, phase I study of PF‐06647263, an anti‐EFNA4 calicheamicin antibody–drug conjugate, in patients with advanced solid tumors

    First‐in‐human, phase I study of PF‐06647263, an anti‐EFNA4 calicheamicin antibody–drug conjugate, in patients with advanced solid tumors Autor Ignacio Garrido‐Laguna, Ian E. Krop, Howard A. Burris, Erika Hamilton, Fadi Braiteh, Amy Weise, Maysa Abu‐Khalaf, Theresa L. Werner, Steven Pirie‐Shepherd, Christopher J. Zopf, Mani Lakshminarayanan, Jaymes Holland, Raffaele Baffa, David S. Hong

    Vydáno 2019
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors

    Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors Autor Anthony B. El-Khoueiry, James S. Clarke, Tobias Neff, T. Crossman, Nirav Ratia, Chetan Rathi, Paul Noto, Aarti Tarkar, Ignacio Garrido‐Laguna, Emiliano Calvo, Jordi Rodón, Ben Tran, Peter J. O’Dwyer, Adam Cuker, Albiruni R. Abdul Razak

    Vydáno 2023
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  19. 19
    Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC

    Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC Autor Vaia Florou, Andrew Elliott, Matthew H. Bailey, David Stone, Kajsa E. Affolter, Heloisa P. Soares, Christopher Nevala-Plagemann, Courtney L. Scaife, Phillip Walker, W. Michael Korn, Emil Lou, Rachna T. Shroff, Peter J. Hosein, Ignacio Garrido‐Laguna

    Vydáno 2023
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  20. 20
    652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)

    652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (... Autor Kathryn C. Arbour, Salman Rafi Punekar, Ignacio Garrido‐Laguna, David S. Hong, Brian M. Wolpin, Meredith S. Pelster, M. Barve, Alexander Starodub, D. Sommerhalder, Sam S. Chang, Y. Zhang, Zeena Salman, X. Wang, Corinne E. Gustafson, Alexander I. Spira

    Vydáno 2023
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: